Zimberelimab + Domvanalimab + Etrumadenant
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non Small Cell Lung Cancer
Conditions
Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer
Trial Timeline
Aug 4, 2021 → Jun 30, 2030
NCT ID
NCT04791839About Zimberelimab + Domvanalimab + Etrumadenant
Zimberelimab + Domvanalimab + Etrumadenant is a phase 2 stage product being developed by Arcus Biosciences for Non Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04791839. Target conditions include Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04791839 | Phase 2 | Active |
Competing Products
20 competing products in Non Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Pemetrexed + Carboplatin | Eli Lilly | Phase 3 | 77 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |
| Pemetrexed | Eli Lilly | Pre-clinical | 23 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | 52 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | 33 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | 69 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab | MAIA Biotechnology | Phase 2 | 44 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone | MAIA Biotechnology | Phase 3 | 69 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 52 |
| gemcitabine + carboplatin + cisplatin | Eli Lilly | Phase 2 | 52 |
| Cetuximab | Eli Lilly | Phase 1 | 33 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | 77 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | 52 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | 77 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | 41 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
Other Products from Arcus Biosciences
Casdatifan + Cabozantinib + PlaceboPhase 3
72
Quemliclustat + Placebo + Nab-paclitaxel + GemcitabinePhase 3
72
Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Phase 2
47
Etrumadenant (AB928) + FOLFOX regimen + Zimberelimab (AB122)Phase 2
47
Zimberelimab + DomvanalimabPhase 2
47